C9 anticorps

N° du produit ABIN8065437

L’anticorps anti-C9 Monoclonal Souris est utilisé pour la détection de C9 dans des échantillons de Humain. Il a été validé pour WB, IHC, ELISA et IF.

Aperçu rapide pour C9 anticorps (ABIN8065437)

Antigène: C9 (Complement Component C9 (C9))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp C9 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), ELISA, Immunofluorescence (IF)

Classe de qualité: Carrier-free

Clone: 22

Détail du produit anti-C9 anticorps

Fonction: Anti-Complement C9 Antibody

Specificité: ABS 004-22 is specific for complement factor C9.

Homologie: Human

Purification: Protein A or Protein G purified

Immunogène: Complement factor C9

Isotype: IgG1, kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: 0.01 M phosphate buffer, pH 7.4, with 0.5 M NaCl and 15 mM sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: 2-8°C without exposure to light

Date de péremption: 24 months

Détails sur C9

Antigène: C9 (Complement Component C9 (C9))

Autre désignation: Complement C9

Sujet: C9, ARMD15, C9D, complement component C9, complement component 9,Pore-forming component of the membrane attack complex (MAC), a multiprotein complex activated by the complement cascade, which inserts into a target cell membrane and forms a pore, leading to target cell membrane rupture and cell lysis (PubMed:22832194, PubMed:26841837, PubMed:26841934, PubMed:27052168, PubMed:30552328, PubMed:6177822, PubMed:9212048, PubMed:9634479). The MAC is initiated by proteolytic cleavage of C5 into complement C5b in response to the classical, alternative, lectin and GZMK complement pathways (PubMed:39914456, PubMed:39814882, PubMed:9212048, PubMed:9634479). The complement pathways consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:9212048, PubMed:9634479). Constitutes the pore-forming subunit of the MAC complex: during MAC assembly, C9 associates with the C5b8 intermediate complex, and polymerizes to complete the pore (PubMed:26841934, PubMed:30111885, PubMed:30552328, PubMed:34752492, PubMed:4055801, PubMed:6177822). {ECO:0000269|PubMed:22832194, ECO:0000269|PubMed:26841837, ECO:0000269|PubMed:26841934, ECO:0000269|PubMed:27052168, ECO:0000269|PubMed:30111885, ECO:0000269|PubMed:30552328, ECO:0000269|PubMed:34752492, ECO:0000269|PubMed:39814882, ECO:0000269|PubMed:39914456, ECO:0000269|PubMed:4055801, ECO:0000269|PubMed:6177822, ECO:0000269|PubMed:9212048, ECO:0000269|PubMed:9634479}.,C9,Complement factor C9 is a 71 kDa single-chain ellipsoid a-globular molecule of 558 amino acids including a leader sequence of 20 amino acids. C9 bind the C5b8 complex on membranes and has an unique property in forming tubular structures containing between 12 and 18 monomers, closely resembling the membrane attack complex (MAC). The primary site of synthesis is hepatocytes, secondary sites are monocytes, fibroblasts and glial cells. The normal level of C9 in plasma is 60 μg/mL, and the level is up regulated from hepatocytes by IFN-?.

Poids moléculaire: 71 kDa

ID gène: 735

UniProt: P02748

Pathways: Système du Complément